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Human antibodies to the block 2 region of Plasmodium falciparum merozoite surface protein 1 (MSP1) are
associated with a reduced prospective risk of clinical malaria. Block 2 is highly polymorphic, but all known
alleles can be grouped into three major types. Two of these types (the K1-like and MAD20-like types) contain
type-specific sequences (found in all alleles of a particular type) that flank polymorphic tripeptide repeats.
These repeats contain both type-specific and subtype-specific sequences. To evaluate the antibody recognition
of these parts of block 2, a new panel of six recombinant proteins was used (fused type-specific flanking
sequences and two representative repeat sequences for each of the K1-like and MAD20-like types separately).
Extensive testing of these antigens and full-length block 2 antigens showed that human serum immunoglobulin
G antibodies induced by infection can recognize (i) type-specific epitopes in the repeats, (ii) subtype-specific
epitopes in the repeats, or (iii) type-specific epitopes in flanking sequences. A large prospective study in The
Gambia showed that antibodies to the repeats are strongly associated with protection from clinical malaria.
The results are important for design of a vaccine to induce protective antibodies, and they address hypotheses
about repeat sequences in malaria antigens.
Merozoite surface protein 1 (MSP1) is the most abundant
protein on the surface of the invasive blood stage form of
malaria parasites and is a leading candidate for a vaccine
against Plasmodium falciparum malaria (18). It exists as a non-
covalently linked complex of four fragments (83, 28, 38, and 42
kDa) generated by proteolytic cleavage of a 190-kDa precur-
sor that is membrane anchored by glycosylphosphytidyl inositol
at the C terminus. The primary structure of MSP1 is polymor-
phic, and 40% of the amino acid residues are different in
different allelic forms in P. falciparum (24, 33).
Immunization with MSP1 has been performed with experi-
mental primate challenge models (Aotus and Saimiri models).
Early studies demonstrated that significant protection from
P. falciparum parasite challenge was induced by the whole
190-kDa MSP1 or a large portion of the sequence (19, 31).
Subsequent studies have shown that some protection can be
induced by immunization with recombinant proteins repre-
senting a C-terminal 42-kDa fragment (13) or the cleavage
product MSP119 (22). Naturally acquired human antibodies to
MSP119 have been associated with a reduced risk of clinical
malaria in several studies (1, 8, 14, 16, 29), although not in all
studies (15). Some monoclonal antibodies to MSP119 can in-
hibit merozoite invasion in vitro (3, 4, 35), and a recent study
has shown that a substantial proportion of all naturally ac-
quired human antibodies which inhibit merozoite invasion are
targeted to MSP119 (25). Fewer studies have focused on the
rest of the MSP1 molecule (12, 17, 34), although the N-termi-
nal block 2 region has been found to be under the strongest
natural selection pressure (14), and antibodies specific for
common allelic types of block 2 are strongly associated with a
reduced risk of clinical malaria (14). Moreover, a monoclonal
antibody against block 2 inhibits parasite growth in vitro (23).
The polymorphic block 2 region of MSP1 can be classified
into three main sequence types, K1-like, MAD20-like, and
RO33-like, which range in size from 44 to 89 amino acids (24).
The K1-like and MAD20-like types contain different tripeptide
repeat sequences with serine at the first position, and varia-
tions in the sequence and number of repeats produce subtype
differences within each of these types. The repeats are flanked
by type-specific nonrepetitive sequences (24). Analyses of the
specificities of acquired human antibodies with different full-
length block 2 recombinant proteins have identified type- and
subtype-specific antibodies in sera from individuals in malaria-
endemic areas of Sudan, The Gambia, and Kenya (10–12, 14).
Antibodies from individuals in Senegal have also been shown
to react with a variety of synthetic peptides based on block 2
sequences (20). Understanding the importance of repeat se-
quences is of particular interest, as repeats are present in many
different P. falciparum antigens (36). Although it has been
suggested that repeats might be detrimental to the develop-
ment of protective immune responses (2, 9, 30), high levels of
antibodies against the repeats in the circumsporozoite protein
vaccine antigen are associated with protection from experi-
mental or natural challenge infection in vaccinees (5, 21).
In this paper, recombinant proteins consisting of the MSP1
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block 2 repeat sequences from four alleles (two representatives
of the K1-like type and two representatives of the MAD20-like
type) and proteins consisting of the nonrepeat flanking se-
quences of each of these two types are described. The four
repeat sequence alleles chosen for analysis are the alleles for
which there are existing full-length block 2 antigens and for
which the exact corresponding parasite lines can be cultured
(10). Mice were immunized with these antigens, and the spec-
ificities of antibodies against parasites belonging to different
strains were assayed. The antibody specificities in African adult
sera were determined with these antigens and full-length block
2 antigens, and sera from a large cohort of children were then
studied to identify targets of antibodies associated with pro-
tection from malaria.
MATERIALS AND METHODS
Design and construction of MSP1 block 2 repeat and flanking sequences for
cloning and expression. Six new recombinant proteins (Fig. 1) were designed;
four of these proteins represented repeat sequences, and two represented fused
flanking sequences of the K1-like and MAD20-like types of MSP1 block 2. DNA
sequences for cloning were produced by using the Expand High Fidelity PCR
system (Roche, East Sussex, United Kingdom) with synthetic oligonucleotide
primers, as follows. For the fused K1 flanking sequence, a single-stage PCR was
performed with HB3 genomic DNA as the template and primers K1flankmutF1
(5-GGATCCAATGAAGAAGAAATTACTACAAAAGGTGCAGGCGCCA
GTC-3) and K1flankR1 (5-GAATTCTTAGCTTGCATCAGCTGGAGG-3),
which removed all repeat motifs from the PCR product. For the fused MAD20
flanking sequence, two stages of PCR were performed; the first stage produced
fragments MAD20fg1 and MAD20fg2, which were amplified from genomic DNA
(Wellcome isolate of P. falciparum) by using primer MAD20flankF1 (5-GG
ATCCAATGAAGGAACAAGTGGAAC-3) plus primer MAD20flankR1
(5-TTACCTGAGGCGCCACCCTTTGAACCAGGTGTACT-3) and primer
MAD20flankF2 (5-CAAAGGGTGGCGCCTCAGGTAATTCAAGCAGTAC
AA-3) plus primer MAD20flankR2 (5-TGAATTCTTCCATTGAATTATCTG
AAGG-3). The two fragments were isolated by gel purification and mixed at an
equimolar ratio for a second stage of amplification, in which the fragments were
fused via complementary overhangs in MAD20flankF2 and MAD20flankR1.
The 3D7 and Palo Alto repeats were produced synthetically with two stages of
PCR. The product of the first-stage PCR was extended by using complementary
primers. For the 3D7 repeats the first-stage PCR was performed with comple-
mentary primers 3D7repF1 (5-GGATCCGGCGCCAGTGCGCAGAGTGGC
GCAAGTGCGCAGAGTGGCGCAAGTGCTCAAAGTGGTGCATCCGCT
CAATCC-3) and 3D7repR1 (5-AGACGGACCGCTTGTACCGGACTGCG
CACTCGCACCACTCTGGGCACTTGCACCGGATTGAGCGGCTGCACC
ACTTTG-3), and the product was gel purified and then mixed with an equimo-
lar amount of 3D7repR2 (5-GAATTCTTAGGCGCCTGTACCGGACTGCG
CACTCGCACCACTCTGGGCACTTGCACCGGATTGAGCGGATGCACC
ACTTTGA-3) for the second-stage amplification. For the Palo Alto repeats
the first round of PCR was performed with the complementary primers Palo-
AltorepF1 (5-GGATCCGGCGCCAGTGCTCAAAGCGGCACAAGCGGC
ACAAGCGGCACAAGTGGTACAAGTGGTACAAGTGGTACAAGCGGT
A-3) and PaloAltorepR1 (5-GCACTTGTACCACTTGTACCACTTTGAGC
ACTTGTGCCACTGGTGCCGCTCTGAGCGCTTGTACCGCTTGTACCAC
TTGTACCACTTGTACCACTTG-3), and the product was gel purified and
mixed with an equimolar amount of PaloAltorepR2 (5-GAATTCTTAGGCG
CCTGTACCACTTGTACCACTTGTACCACTTGTACCACTTTGAGCACT
TGTACCACTTGTACCACTTTGAGC-3) for the second-stage PCR. The
MAD20 and Wellcome repeats were produced synthetically by PCR elongation
by using the following complementary primer pairs: MAD20repF1 (5-GGATC
CGGCGCCTCTGTTACTTCAGGTGGTTCAGTTGCTTCAGTTGCCTCC
GTTGCTTCAGGTGGTAGC-3) plus MADrepR1 (5-GAATTCTTAGGCG
CCGCCGCCTGAAGCAACTGAGCCACCGCTACCACCTGAAGCAACGG
AGGC-3) and WellcomerepF1 (5-GGATCCGGCGCCTCAGTTGCTTCAG
GTGGTTCAGGTGGCTCAGTTGCTTCAGGTGGCTCAGTTGC-3) plus
WellcomerepR1 (5-GAATTCTTAGGCGCCACCACCTGAAGCTACCGAG
CCGCCGGAAGCTACCGAGCCGCCGGAAGCAACTGAGCCACCTGAA
GCAACTGA-3), respectively.
Production and purification of recombinant proteins. All DNA products were
cloned into the PCR cloning vector pGEM T (Promega, Southampton, United
Kingdom), and transformations were done in Escherichia coli competent strain
JM109 before sequencing to ensure the fidelity of each construct. Each coding
region was excised with BamHI and EcoRI by using sites engineered into the
primers before cloning into the complementary sites of pGEX-2T (32). Cloned
recombinant plasmids were sequenced to ensure complete fidelity and then used
to transform E. coli host strain BL21 for optimal expression of the recombinant
proteins, which was achieved after 4 h of incubation with 0.2 mM isopropyl--
D-thiogalactopyranoside (IPTG). Bacterial sonicates were prepared, and this was
followed by purification of glutathione S-transferase (GST) fusion proteins by
using glutathione Sepharose beads in bulk pack columns (Amersham Pharmacia
Biotech). Purified fractions of each recombinant protein were pooled, the con-
centrations were determined by the Protein Assay (Bio-Rad Ltd.), and the
preparations were analyzed by sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis.
Immunization of mice and assays of murine antibodies. Outbred MF1 and
inbred CBA/Ca mice were immunized with the new block 2 recombinant proteins
by using a protocol similar to that described elsewhere (10). Briefly, each purified
block 2 fusion protein was diluted with phosphate-buffered saline (PBS) to a
concentration of 1 mg ml1, and 3 volumes of Imject Alum (Perbio Science UK,
Cheshire, United Kingdom) was added and allowed to mix for 30 min at room
temperature. The antigen-adjuvant mixture was administered intraperitoneally;
five MF1 and five CBA/Ca mice were immunized with each protein (50 g per
dose in a final volume of 200 l). Three doses were administered at monthly
intervals, and blood was collected before immunization and 12 to 14 days after
each dose. The specific antiparasite reactivities of all sera from the final bleed
were assessed by performing an immunofluorescence assay (IFA) as described
previously (10). Briefly, multiwell slides of schizonts were prepared from cultured
P. falciparum strains Palo Alto, 3D7, Wellcome, and MAD20; the purity and
identity of each strain were confirmed by PCR and sequencing of MSP1 block 2
from genomic DNA; and slides were acetone fixed and air dried. Six serial
doubling dilutions of the murine sera (1/50 to 1/1,600) in PBS with 1% bovine
serum albumin (20 l/well) were tested. Fluorescein isothiocyanate-conjugated
goat anti-mouse immunoglobulin G (IgG) (Jackson ImmunoResearch) was used
as the second antibody at a 1/200 dilution, and slides were mounted in Vector-
shield mounting medium with 4,6-diamidino-2-phenylindole (DAPI) (Vector
Laboratories, Inc., Burlingame, Calif.) and examined with a fluorescence micro-
scope at a magnification of1,000. The endpoint titer of each serum was defined
as the highest dilution that resulted in bright and clear schizont-specific fluores-
cence; sera that were positive at a dilution of 1/1,600 were retested at higher
dilutions to determine their endpoint titers.
Reactivities of recombinant proteins with human antibodies. Sera from 38
adults living in malaria-endemic areas of Lagos, Nigeria, were assayed for IgG
reactivity to MSP1 block 2 recombinant antigens. The adults (ages, 18 to 60
years) each gave informed consent to donate a 20-ml venous blood sample while
accompanying their children at the Massey Street Children’s Hospital, Lagos
FIG. 1. (A) Schematic representation of MSP1 block 2 repeat and flanking sequence fusion proteins used in this study. Primary amino acid
sequences are shown, and they start immediately downstream of the GST fusion partner sequence (the BamHI site was used to clone the inserts
into PGEX-2T). Note that each flanking sequence construct is a fusion of the left and right flanking sequences. The asterisks represent NarI sites
(which encode a glycine and an alanine) created to allow the sequences to be rearranged in a modular format for further work. (B) Titers, as
determined by IFA (against P. falciparum schizonts), of serum IgG in mice (CBA/Ca and MF1 strain individuals) immunized with each of the
K1-like block 2 repeat antigens or flanking sequence antigen. The reactivities against parasites with K1-like block 2 alleles (isolates Palo Alto and
3D7) are shown; the reactivities against parasites with MAD20-like block 2 alleles (isolates Wellcome and MAD20) were negative. (C) Titers, as
determined by IFA (against P. falciparum schizonts), of serum IgG in mice (CBA/Ca and MF1 strain individuals) immunized with each of the
MAD20-like block 2 repeat antigens or flanking sequence antigen. The reactivities against parasites with MAD20-like block 2 alleles (isolates
Wellcome and MAD20) are shown; the reactivities against parasites with K1-like block 2 alleles (isolates Palo Alto and 3D7) were negative.
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Island; approval of the ethical committee of the National Institute for Medical
Research, Nigeria, was obtained. The adults did not have malaria at the time of
sampling (July and August 1997), but all of them reported a previous history of
malaria, and a high proportion had antibodies to P. falciparum antigen EBA-175
(26). The antigens used included the six novel recombinant proteins listed above
plus the four corresponding full-length block 2 constructs (of the K1-like and
MAD20-like types) characterized previously: MAD20, Wellcome, Palo Alto, and
3D7 (10–12). The allele frequencies of the K1-like and MAD20-like types of
MSP1 block 2 in a nearby area of southwest Nigeria have been described to be
0.52 and 0.29, respectively (14). The sera were tested in duplicate with each
antigen by using a protocol described previously (10). Briefly, 50 ng of recom-
binant antigen per well was coated overnight at 4°C in 100 l of coating buffer (15
mM Na2CO3, 35 mM NaHCO3; pH 9.3) onto Immunolon 4HBX flat-bottom
microtiter plates (Dynex Technologies Inc). The plates were washed (in PBS with
0.05% Tween 20), blocked (with 1% skim milk) for 5 h, and washed again. Sera
were diluted 1/500 in blocking buffer, and duplicate 100-l aliquots were incu-
bated overnight at 4°C in antigen-coated wells. The wells were washed and then
incubated with 100 l of horseradish peroxidase-conjugated rabbit anti-human
IgG (at a dilution of 1/5,000) (Dako Ltd.) before detection with O-phenylene-
diamine–H2O2 (Sigma). The mean optical density of each serum-antigen reac-
tion mixture was calculated after correction for binding of the serum to GST
alone (the background optical density was generally 0.1). A serum was scored
positive if the corrected optical density was higher than the mean plus 3 standard
deviations of values for 20 negative control sera from United Kingdom residents
who had never had malaria. By using selected positive sera, competition enzyme-
linked immunosorbent assays (ELISAs) for pairs of antigens were carried out to
define the specificities of the antibodies. The protocol was identical to that used
for direct ELISAs except that sera diluted 1/500 were preincubated with soluble
competing antigens at concentrations ranging from 0 to 10 g ml1 for 5 h before
incubation overnight with 50 ng of plate-bound antigen.
Prospective study of antibody reactivities and incidence of malaria in The
Gambia. A cohort of 334 Gambian children (ages, 3 to 7 years) were monitored
for clinical malaria by active and passive case detection throughout the annual
malaria transmission season in 1996 (from June to November). Sera were col-
lected in June for analysis of antibody reactivities prior to this. The subjects or
their guardians gave informed consent, and the study was approved by the
Scientific Co-ordinating Committee of the Medical Research Council in The
Gambia and the Joint Ethical Committee of the Medical Research Council and
Gambian Government. Clinical malaria was defined as a P. falciparum para-
sitemia of 	5,000 parasites l1 occurring at the same time as a febrile episode
with an axillary temperature of 	37.5°C, the definition normally used in studies
of endemic malaria in West Africa (14, 15, 29). This was the same cohort
previously studied for antibodies to full-length block 2 antigens (14) except that
three sera that were tested previously were no longer available. The allele
frequencies of the K1-like and MAD20-like types of MSP1 block 2 in this area
have been described to be 0.51 and 0.33, respectively (14). Sera were tested in
duplicate by ELISAs to determine the reactivities with the six new MSP1 block
2 recombinant proteins (MAD20 repeats, Wellcome repeats, 3D7 repeats, Palo
Alto repeats, MAD20-like flanking sequence, and K1-like flanking sequence).
The mean optical density was corrected for binding to GST, and positive results
were scored by using the criteria outlined above. ELISA results were imported
into an EXCEL worksheet by investigators blinded from the epidemiological
data (kept separately on a STATA file). The data files were merged, and after
this univariate and multivariate statistical analyses were performed with EPI-
INFO, version 6, and SPSS, version 9.0.
RESULTS
Characterization of the MSP1 block 2 repeat and flanking
sequence antigens. The six new recombinant GST fusion pro-
teins (Fig. 1A) were expressed as single products of the ex-
pected size after purification, as determined by reducing so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis.
Groups of mice (strains CBA/Ca and MF1) were immunized
with each of these proteins, and their specific antibody reac-
tivities against schizonts of different P. falciparum isolates were
determined by IFA endpoint titration (Fig. 1B and C). The
Palo Alto repeat and 3D7 repeat antigens (both K1-like type)
induced antibodies specific for Palo Alto and 3D7 parasites,
respectively (i.e., predominantly subtype-specific antibodies);
the mice immunized with the Palo Alto repeats had higher
titers against the Palo Alto parasites than against the 3D7
parasites (P 
 0.012, as determined by the Wilcoxon signed
rank test), and the mice immunized with the 3D7 repeats had
higher titers against the 3D7 parasites than against the Palo
Alto parasites (P 
 0.041, as determined by the Wilcoxon
signed rank test) (Fig. 1B). The K1-like flanking antigen in-
duced type-specific antibodies against both these K1-like par-
asites (Fig. 1B). None of the K1-like antigens induced antibod-
ies to MAD20-like parasites or vice versa. Immunization with
the Wellcome repeat antigen or the MAD20 repeat antigen
induced antibodies in most mice that reacted with both the
Wellcome and MAD20 parasites (a predominantly type-spe-
cific response); the titers to the Wellcome and MAD20 para-
sites were not significantly different in each of these groups
(P 	 0.2 for each comparison, as determined by the Wilcoxon
signed rank test) (Fig. 1C). Mice immunized with the MAD20
flanking region protein were negative or had very low reactiv-
ities (Fig. 1C). The broad type specificity of antibodies reactive
to MAD20-like repeat antigens contrasts with the predominant
subtype specificity of antibodies to K1-like repeat antigens.
Specificity of human serum IgG to MSP1 block 2 full-length,
repeat, and flanking sequence antigens. Thirty-eight adult
Nigerian sera were tested against the new block 2 repeat and
flanking sequence antigens and against the corresponding full-
length block 2 antigens previously described (10). Eighteen
(47%) of the 38 sera were positive with one or more of the
antigens as determined by ELISA. The specificities of antibod-
ies to the K1-like and MAD20-like antigens are shown in Fig.
2 and 3, respectively.
Fifteen of the 38 sera contained antibodies against the full-
length K1-like block 2 antigens (10 sera recognized both full-
length Palo Alto and 3D7 antigens, and 5 sera recognized only
the Palo Alto antigen) (Fig. 2A). As expected, sera specific for
the Palo Alto antigen reacted with epitopes within the repeat
sequences (positive for the Palo Alto but not the 3D7 repeats).
Of the sera that showed broader specificity, four recognized
the K1-like flanking sequence antigen, and four others recog-
nized both Palo Alto and 3D7 repeats. There were differences
in the levels of antibodies to the Palo Alto and 3D7 antigens in
the latter four sera, although they were positive for both. Fig-
ure 2B shows the specificity of antibodies in serum N1, as
determined by a competition ELISA, which recognized the
Palo Alto repeats strongly and the 3D7 repeats very weakly. In
contrast, serum N20 had a predominant reactivity to 3D7 re-
peats and weaker reactivities to Palo Alto repeats and epitopes
on full-length antigens (Fig. 2C). Other sera also showed dif-
ferences in the antibody reactivities to the Palo Alto and 3D7
repeats, and no serum contained antibodies that were able to
bind these two sequences similarly. Thus, antibodies to these
two K1-like repeats were mostly subtype specific.
In contrast, the antibody reactivities to the block 2 MAD20-
like antigens exhibited relatively broad type specificity. Ten
sera tested positive with one or more of the antigens (Fig. 3A),
and seven of these sera recognized both full-length block 2
antigens. Antibodies in these sera reacted with the repeats.
When sera were analyzed by competition ELISA, it was ap-
parent that the majority of the reactivity was due to antibodies
which recognized both MAD20 and Wellcome repeats, al-
though there were some detectable differences in the abilities
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of the antigens to compete (examples for sera N20 and N15 are
shown in Fig. 3B and C, respectively).
Reactivities of IgG in sera from African children to MSP1
block 2 repeat and flanking sequence antigens. The MSP1
block 2 repeat and flanking sequence antigens were tested with
sera from 334 Gambian children who were between 3 and 7
years old and were sampled shortly before the start of the
annual malaria transmission season in 1996. These sera had
previously been studied for reactivity to full-length MSP1 block
2 antigens (14). The overall patterns of reactivities to MSP1
block 2 antigens were similar to those seen in the Nigerian
adult sera. Specific antibodies to each of the repeat antigens
and the K1-like flanking sequence were commonly detected,
but there was little reactivity with the MAD20-like flanking
sequence. Figure 4 shows the levels of absorbance (optical
density) for IgG reactivity in all sera with all tested repeat
antigens, flanking sequence antigens, and representative full-
length antigens for each of the K1-like and MAD20-like block
2 types.
Correlations between the reactivities to pairs of antigens
were analyzed (Fig. 4). There were moderately strong corre-
lations between the reactivities of the full-length antigens and
FIG. 2. Reactivities as determined ELISA of Nigerian adult sera with K1-like antigens. (A) Reactivities of all sera which were positive for one
or more K1-like antigens. Positive ELISA optical density (OD) values are the values above the cutoff defined for each antigen by the mean plus
3 standard deviations for negative control sera (the cutoff values were generally 0.1). (B) Competition ELISA showing that serum N1 has
reactivity specific for the Palo Alto repeats and very low cross-reactivity to the 3D7 repeats. (C) Competition ELISA showing that serum N20 has
predominant reactivity to the 3D7 repeats and less reactivity to epitopes that are on the full-length antigens and on the Palo Alto repeats.
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the corresponding repeats for the K1-like antigens (r
 0.53 for
Palo Alto repeats versus Palo Alto full-length antigen; r 
 0.70
for 3D7 repeat versus 3D7 full-length antigen) (Fig. 4A). The
correlations between the reactivities of full-length and repeat
MAD20-like antigens were stronger (r 
 0.86 for MAD20
repeat versus MAD20 full-length antigen; r 
 0.92 for Well-
come repeat versus Wellcome full-length antigen) (Fig. 4B).
Strong correlations for reactivities to K1-like flanking se-
quence and K1-like full-length antigens were also seen (r 

0.75 for Palo Alto; r 
 0.62 for 3D7) (Fig. 4C). In contrast,
FIG. 3. Reactivities of Nigerian adult sera with MAD20-like antigens. (A) Reactivities of all sera positive for one or more MAD20-like antigens.
Positive ELISA optical density (OD) values are the values above the cutoff defined for each antigen by the mean plus 3 standard deviations for
negative control sera (the cutoff values generally were 0.1). (B) Competition ELISA showing that serum N20 has reactivity to epitopes shared
by the MAD20 and Wellcome repeats and that the Wellcome repeats have greater competitive binding ability. (C) Competition ELISA showing
that serum N15 similarly has reactivity with epitopes shared by the MAD20 and Wellcome repeats. Again, the competitive binding by Wellcome
repeats is greater.
FIG. 4. Correlation of reactivities of sera from Gambian children who were 3 to 7 years old (n 
 334) with pairs of recombinant proteins
containing different MSP1 block 2 sequences. Examples are shown for K1-like block 2 type proteins in panels A, C, and E and for the MAD20-like
block 2 type proteins in panels B, D, and F. Absorbance (optical density) values for IgG reactions with each antigen were plotted for pairwise
combinations of antigens, as follows: repeats versus full-length antigens (A and B); flanking sequences versus full-length antigens (C and D); and
different repeat sequences within a type (E and F). The dashed lines indicate the cutoff values for positive reactions (defined as the mean plus 3
standard deviations for European control values). Pearson’s correlation coefficients (r values) are shown.
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there were only weak antibody reactivities to the MAD20-like
flanking sequence protein, and these reactivities did not cor-
relate well with antibody reactivities to the full-length antigens
(r 
 0.30 for the correlation with MAD20 full-length block 2;
r 
 0.22 for the correlation with Wellcome full-length block 2)
(Fig. 4D). The lower correlations between the reactivities of
the K1-like full-length and repeat antigens than between the
reactivities of the MAD20-like full-length and repeat antigens
can be explained by the sera that bind only to the K1-like
flanking sequence. No serum that had strong reactivity to a
K1-like full-length antigen failed to recognize either the re-
peats or the flanking region (sera represented by points at the
bottom right of the scatter plot in Fig. 4A are represented by
points at the top right of the scatter plot in Fig. 4C and vice
versa).
There was a very strong correlation between the reactivities
to the two MAD20-like repeat antigens (MAD20 and Well-
come; r 
 0.83) (Fig. 4F), suggesting that a high proportion of
antibodies react with both. This is consistent with the cross-
reactivities in sera of Nigerian adults as determined by com-
petition ELISAs. For the K1-like repeat antigens (Palo Alto
and 3D7), the correlation was lower (r 
 0.60) (Fig. 4E),
suggesting that a high proportion of antibodies against K1-like
repeats recognize subtype-specific epitopes. This is also con-
sistent with the reactivities in Nigerian adult sera revealed by
competition ELISAs.
Relationship between antibodies to MSP1 block 2 repeat
and flanking sequence antigens and subsequent incidence of
malaria. The IgG reactivities to each of the block 2 antigens in
the Gambian children in June prior to the malaria transmission
season were tested for associations with the subsequent inci-
dence of clinical malaria in the children throughout the ma-
laria transmission season (July to November). Table 1 shows
that the presence of IgG to the Wellcome, 3D7, and Palo Alto
repeats was significantly associated with a lower risk of clinical
malaria (the relative risk values were significantly less than
1.0). These protective associations remained statistically signif-
icant when age was accounted for as a confounding variable by
multivariate (logistic regression) analysis. Inclusion of other
variables (such as the presence of P. falciparum parasitemia at
the time of serum sampling prior to the transmission season) in
multivariate analysis did not alter these associations. The pres-
ence of IgG to the MAD20 repeats showed a nonsignificant
trend towards protection. When the optical densities (rather
than just positive reactions) for the MAD20 repeats were an-
alyzed, there was a significant correlation with protection (P 

0.014, as determined by univariate analysis; P 
 0.026 after
adjustment for age, as determined by multivariate analysis).
The antibody reactivities to K1-like or MAD20-like flanking
sequence proteins were not associated with protection, based
on analysis of either antibody positive reactions or optical
densities.
The presence of antibodies to different repeat sequences was
associated with protection in an additive manner (Table 2).
Individuals with antibody reactivity to only one or two of the
different repeat antigens did not have a significantly lower risk
of malaria than individuals with no antibodies. However, indi-
viduals with antibodies to three or more of the repeat antigens
had a very significantly lower risk of malaria (relative risk, 0.20;
95% confidence interval, 0.06 to 0.75; P 
 0.0002). This was
particularly due to the fact that individuals had antibodies to
repeat antigens of both K1-like and MAD20-like types. For
example, individuals with antibodies to both the 3D7 repeats
(K1-like type) and the Wellcome repeats (MAD20-like type)
had a very low prospective risk of clinical malaria, correspond-
ing to a relative risk of 0.26 (95% confidence interval, 0.06 to
0.77), compared with individuals who had neither (P 
 0.003,
as determined by univariate analysis; P 
 0.008 after adjust-
ment for age, as determined by multivariate analysis). Simi-
larly, individuals with antibodies to both the Palo Alto repeats
(K1-like type) and the MAD20 repeats (MAD20-like type) had
TABLE 1. Proportions of Gambian children acquiring clinical malaria in July to November in groups with or
without serum IgG to different parts of MSP1 block 2 in June
MSP1 recombinant
antigen
% Acquiring clinical malariaa Relative risk
(95% confidence interval)
Univariate
P value
Age-corrected
P valueIgG-positive individuals IgG-negative individuals
K1-like block 2
Flanking nonrepeats 46.9 (15/32) 55.0 (166/302) 0.85 (0.58–1.25) 0.38 0.55
Palo Alto repeats 27.3 (9/33) 57.1 (172/301) 0.48 (0.27–0.84) 0.001 0.014
3D7 repeats 32.4 (11/34) 56.7 (170/300) 0.57 (0.35–0.94) 0.007 0.047
MAD-like block 2
Flanking nonrepeats 56.8 (42/74) 53.5 (139/260) 1.06 (0.84–1.33) 0.62 0.36
Wellcome repeats 32.5 (13/40) 57.1 (168/294) 0.57 (0.36–0.90) 0.003 0.012
MAD20 repeats 41.3 (19/46) 56.3 (162/288) 0.73 (0.51–1.05) 0.059 0.192
a A total of 334 children were studied. The values in parentheses are number who acquired clinical malaria/total numbers who were IgG positive or IgG negative
for the given antigen.
TABLE 2. Serum IgG reactivity to multiple MSP1 block 2 repeat
antigens before the transmission season is associated
with protection in an incremental manner
No. of
repeat antigens
recognized
No. of
sera
No. (%) of
individuals getting
malaria
Relative risk
(95% confidence
interval)
P value
0 253 146 (58) 1
1 38 22 (58) 1.00 (0.75–1.34) 0.98
2 26 11 (42) 0.73 (0.46–1.16) 0.13
3 5 0 (0) 0 () 0.015
4 12 2 (17) 0.29 (0.08–1.03) 0.005
3 or more 17 2 (12) 0.20 (0.06–0.75) 0.0002
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a very low prospective risk of clinical malaria, corresponding to
a relative risk of 0.37 (95% confidence interval, 0.13 to 1.01),
compared with individuals who had neither (P 
 0.007, as
determined by univariate analysis; P 
 0.039 after adjustment
for age, as determined by multivariate analysis).
DISCUSSION
In this study we used new recombinant proteins to dissect
the structure of P. falciparum MSP1 block 2 and to map the
specificity of antibodies associated with protection in humans.
The results have implications for vaccine design because they
demonstrate the importance of the block 2 polymorphic repeat
sequences in naturally acquired immunity and provide an as-
sessment of the cross-reactivity of human antibodies to these
sequences.
Previously, immunization of mice with full-length block 2
antigens resulted in mainly type-specific IgG responses (10),
and type specificity was also predominantly seen here in re-
sponse to MAD20-like repeat sequences (antibodies recogniz-
ing both Wellcome and MAD20 repeats) and the K1-like
flanking sequence. However, the responses to the K1-like re-
peats were mainly subtype specific (discriminating between
Palo Alto and 3D7 repeats), indicating that these two repeats
are more antigenically distinct, as expected from their primary
sequences (Fig. 1). Immunization with the MAD20-like flank-
ing sequence protein elicited IgG with a low titer or no reac-
tivity against parasites as determined by IFA, indicating either
that B-cell epitopes are not present in the sequence or that the
recombinant protein does not reflect the native structure of
such epitopes.
Human sera from individuals in malaria-endemic popula-
tions in Nigeria and The Gambia showed clear and consistent
patterns of reactivities with the MSP1 block 2 recombinant
proteins. For the MAD20-like antigens, type-specific antibod-
ies were seen in the majority of positive sera and reacted with
sequences common to the Wellcome and MAD20 repeats. No
or very weak reactivities with the MAD20-like flanking se-
quence protein were the rule, which is consistent with the
observation that almost all antibodies against MAD20-like an-
tigens were directed against the repeats. We cannot eliminate
the possibility that there might be epitopes in the flanking
sequence that were not represented by the recombinant flank-
ing sequence protein, although if such epitopes exist, they must
be rarely recognized. With K1-like proteins, type-specific an-
tibodies against the flanking sequences were detected, and
antibodies against the repeats were more predominantly sub-
type specific (discriminating between Palo Alto and 3D7).
The strong associations between reactivity of antibodies to the
individual MSP1 block 2 repeat antigens and a lower prospective
risk of clinical malaria shown here indicate that the repeat se-
quences contain protective antibody epitopes. It is important that
these protective associations remained significant after adjust-
ment for age of individuals and the presence of pretransmission
season parasitemia. In addition to the protective associations of
antibodies to each of the repeat antigens separately, there was an
additive effect. In particular, the individuals with reactivities to
repeats of both types (K1-like and MAD20-like) were much less
likely to have malaria during follow-up. It has recently been
shown that the human antibodies to MSP1 block 2 are predom-
inantly IgG3 (12, 20), a cytophilic subclass implicated in protec-
tion from malaria (7). Antibody responses to MSP1 have been
shown to be short-lived in some studies (11, 17), and it has been
proposed that the short half-life of serum IgG3 may contribute to
this (12). Such antibodies could have a transient effect in control-
ling existing parasitemia but might not provide long-term protec-
tion against subsequent infections. The length of time that
antibody levels last after infection is therefore an important
area for further investigation, and there may be differences
among populations (20).
It has been suggested that there may be cross-reactivities be-
tween B-cell epitopes on different repeat structures of P. falcipa-
rum antigens and that these cross-reactivities could prevent the
development of effective antibodies (2) by interfering with affinity
maturation of B cells. In contrast, results obtained in this study
show that antibodies to the different MSP1 block 2 repeats are
highly specific and not cross-reactive between the major allelic
types (K1-like and MAD20-like) or even between certain sub-
types of the K1-like sequences. In another hypothesis workers
have proposed that immunodominant repeats could divert the
human immune response away from more important targets of
immunity (a distraction which has been likened to a smoke
screen) (2, 9). However, the highly significant association between
antibodies to the MSP1 block 2 repeats and the reduced risk of
malaria shown in this study is evidence that B-cell responses
to these repeats are effective in immune protection. Thus,
the data do not support the inhibition of affinity maturation
hypothesis or the immunodominant smoke screen hypothe-
sis for the repeats of MSP1 block 2.
Rational vaccine design requires a comprehensive under-
standing of the repertoire of naturally occurring antigenic
structures and evaluation of whether naturally occurring im-
mune responses are protective. It is clear that any vaccine
based on MSP1 block 2 sequences needs to protect against the
whole spectrum of parasites with the divergent MSP1 block 2
sequences that occur naturally (24). Such a vaccine should
include repeat motifs from MAD20-like and K1-like types in
order to generate antibodies with specificities similar to those
described here. A third allelic type (the RO33-like type, which
does not contain repeats) requires further study as antibodies
against this type have not yet been associated with protection
(14), although asymptomatic infection by parasites with the
RO33-like allele has been associated with a reduced risk of
clinical malaria (9). It will be important to further characterize
the fine specificity of antibodies to each of these types and to
determine whether these antibodies are associated with pro-
tection from malaria in other populations.
Effector mechanisms of antibodies against MSP1 are pri-
marily thought to involve inhibition of erythrocyte invasion by
merozoites (23, 25, 34), but a potential role of monocytes in
antibody-dependent inhibition of parasite growth may also be
important (6). To elicit lasting antibody responses by immu-
nization, helper T-cell responses are also required. T-cell
reactivities to MSP1 block 2 have not been identified yet, but
T-cell epitopes in proximal sequences of block 1 (27, 28) are
promising candidates for inclusion with block 2 antibody
epitope sequences in an experimental vaccine. Other aspects
of formulation, including potential combination with C-ter-
minal MSP1 sequences, require downstream empirical in-
vestigation.
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